Hervé Hoppenot

Welcome Hervé Hoppenot as Chairman of our Board of Directors, succeeding Charles Homcy, M.D., who will remain on the Board. Hervé’s decades of experience will be invaluable as we approach major milestones in 2026. ir.mazetx.com/news-releases/…

Working from home.. 😅

Learn more about the positive data we shared on our novel, first-in-class mutant calreticulin (mutCALR) targeted monoclonal antibody in patients with essential thrombocythemia (ET) at the @EHA_Hematology Congress. #EHA2025 investor.incyte.com/news-releases/…

On a day in #LIPAFC history: As seen in this recently discovered newsreel footage, Antoine Hoppenot ties the game in the 94th minute of the Eastern Conference Final with one of the most storied goals in the rivalry's history. City went on to win 3-1 in extra time.

Proud to see Axatilimab data at ASH Plenary session presented by Dr Wolff

Soccer legend @MiaHamm helps shed light on the experiences of people living with GVHD, like Rollin and Loriana, and how their fans - family and friends - have supported them through their journey.

#News: We’ve announced with @Syndax positive topline results from the Phase 2 AGAVE-201 trial of axatilimab in patients with refractory chronic graft-versus-host disease (#GVHD). bit.ly/3rxYZpi

We're #IncyteProud to be recognized by @AmerChemSociety as one of the 2023 #HeroesOfChemistry for developing the first treatment for certain myeloproliferative neoplasms (#MPNs), a group of rare blood cancers, and acute and chronic graft-versus-host disease (#GVHD).

2023 ACS #HeroesofChemistry Winners Announced! Congrats to @abbvie, @honeywell, @Incyte, @Merck, @VertexPharma, & @ViiVHC for developing products that led to advancements in improving #health & the #environment. Learn more at fal.cn/3A1aE #Chemistry #Science

Living with #vitiligo can be difficult, but hearing different perspectives may help. Learn more at ThisIsVitiligo.com.

We’re #IncyteProud to be named to @USATODAY’s inaugural America’s Climate Leaders list! We’re committed to operating our business in a sustainable way. See the full list. bit.ly/43iXwB6

As an oncologist, I've seen how the costs of #cancer are literally killing patients. We must end this financial toxicity by requiring that private & public payers eliminate all deductibles, co-pays, or other cost-sharing upon a cancer diagnosis. 🧵 statnews.com/2023/05/23/fin…

Meet Berardo. Berardo, now 41, was diagnosed with #vitiligo at just ten years old. Hear his story and learn more about his experience living with this chronic autoimmune condition.

Hear from David Rosmarin, MD, Vice Chair of Research and Education, Department of Dermatology at @TuftsMedicalCtr, as he shares his perspective on the @NEJM publication of the Phase 3 results from the TRuE-V clinical trial program in #vitiligo.

#News: @NEJM published Phase 3 results from the TRuE-V clinical trial program, showing significant improvements in facial and total body repigmentation with our #vitiligo treatment.

The @US_FDA approved our treatment for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Read our press release to learn more.

#Breaking: The @US_FDA has approved our treatment for #vitiligo.

#News: We’ve announced with @Novartis that the @EU_Commission has approved a new targeted therapy option for previously treated patients in Europe who are living with advanced non-small cell lung cancer (NSCLC). Learn more. bit.ly/3zURAT6

Incyte has been named as one of the Top 100 Most Loved Workplaces of 2021 by @Newsweek. We are thankful for our employees’ collaboration & commitment to patient-focused innovation. bit.ly/3E0Gg6K

#Breaking: The @US_FDA has approved our new innovative therapy for certain patients with mild to moderate #AtopicDermatitis, the most common type of #Eczema.